Qiagen: Invest Securities reduces target price

(CercleFinance.com) - Invest Securities maintains its "neutral" rating on the pharmaceutical research and diagnostics firm Qiagen's shares, trimming its target price for them, from E45 to E43.


The analyst says that the quarterly publication reflects the group's resilience, with robust results underpinned by its main growth pillars.

Nevertheless, this is not encouraging in view of the lack of visibility on the OEM segment and the outlook for China, which have prompted the company to reduce its targets, Invest points out.


Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.